Abstract
Cellular senescence is an irreversible arrest of proliferation. It is activated when a cell encounters stress such as DNA damage, telomere shortening or oncogene activation. Like apoptosis, it impedes tumour progression and acts as a barrier that pre-neoplastic cells must overcome during their evolution toward the full tumourigenic state. This review focuses on the role of transcriptional regulators in the control of cellular senescence, explores how their function is perturbed in cancer and discusses the potential to harness this knowledge for future cancer therapies.
This is a preview of subscription content, access via your institution
Access options
Subscribe to this journal
Receive 50 print issues and online access
$259.00 per year
only $5.18 per issue
Buy this article
- Purchase on Springer Link
- Instant access to full article PDF
Prices may be subject to local taxes which are calculated during checkout
Similar content being viewed by others
References
Agger K, Cloos PA, Rudkjaer L, Williams K, Andersen G, Christensen J et al. (2009). The H3K27me3 demethylase JMJD3 contributes to the activation of the INK4A-ARF locus in response to oncogene- and stress-induced senescence. Genes Dev 23: 1171–1176.
Alani RM, Young AZ, Shifflett CB . (2001). Id1 regulation of cellular senescence through transcriptional repression of p16/Ink4a. Proc Natl Acad Sci USA 98: 7812–7816.
Aslanian A, Iaquinta PJ, Verona R, Lees JA . (2004). Repression of the Arf tumor suppressor by E2F3 is required for normal cell cycle kinetics. Genes Dev 18: 1413–1422.
Bachmann IM, Halvorsen OJ, Collett K, Stefansson IM, Straume O, Haukaas SA et al. (2006). EZH2 expression is associated with high proliferation rate and aggressive tumor subgroups in cutaneous melanoma and cancers of the endometrium, prostate, and breast. J Clin Oncol 24: 268–273.
Bachmann IM, Puntervoll HE, Otte AP, Akslen LA . (2008). Loss of BMI-1 expression is associated with clinical progress of malignant melanoma. Mod Pathol 21: 583–590.
Bannister AJ, Zegerman P, Partridge JF, Miska EA, Thomas JO, Allshire RC et al. (2001). Selective recognition of methylated lysine 9 on histone H3 by the HP1 chromo domain. Nature 410: 120–124.
Barradas M, Anderton E, Acosta JC, Li S, Banito A, Rodriguez-Niedenfuhr M et al. (2009). Histone demethylase JMJD3 contributes to epigenetic control of INK4a/ARF by oncogenic RAS. Genes Dev 23: 1177–1182.
Bartkova J, Rezaei N, Liontos M, Karakaidos P, Kletsas D, Issaeva N et al. (2006). Oncogene-induced senescence is part of the tumorigenesis barrier imposed by DNA damage checkpoints. Nature 444: 633–637.
Bea S, Tort F, Pinyol M, Puig X, Hernandez L, Hernandez S et al. (2001). BMI-1 gene amplification and overexpression in hematological malignancies occur mainly in mantle cell lymphomas. Cancer Res 61: 2409–2412.
Ben-Porath I, Thomson MW, Carey VJ, Ge R, Bell GW, Regev A et al. (2008). An embryonic stem cell-like gene expression signature in poorly differentiated aggressive human tumors. Nat Genet 40: 499–507.
Bennecke M, Kriegl L, Bajbouj M, Retzlaff K, Robine S, Jung A et al. (2010). Ink4a/Arf and oncogene-induced senescence prevent tumor progression during alternative colorectal tumorigenesis. Cancer Cell 18: 135–146.
Bishop CL, Bergin AM, Fessart D, Borgdorff V, Hatzimasoura E, Garbe JC et al. (2010). Primary cilium-dependent and -independent Hedgehog signaling inhibits p16(INK4A). Mol Cell 40: 533–547.
Blais A, Dynlacht BD . (2007). E2F-associated chromatin modifiers and cell cycle control. Curr Opin Cell Biol 19: 658–662.
Bracken AP, Ciro M, Cocito A, Helin K . (2004). E2F target genes: unraveling the biology. Trends Biochem Sci 29: 409–417.
Bracken AP, Helin K . (2009). Polycomb group proteins: navigators of lineage pathways led astray in cancer. Nat Rev Cancer 9: 773–784.
Bracken AP, Kleine-Kohlbrecher D, Dietrich N, Pasini D, Gargiulo G, Beekman C et al. (2007). The Polycomb group proteins bind throughout the INK4A-ARF locus and are disassociated in senescent cells. Genes Dev 21: 525–530.
Bracken AP, Pasini D, Capra M, Prosperini E, Colli E, Helin K . (2003). EZH2 is downstream of the pRB-E2F pathway, essential for proliferation and amplified in cancer. EMBO J 22: 5323–5335.
Braig M, Lee S, Loddenkemper C, Rudolph C, Peters AH, Schlegelberger B et al. (2005). Oncogene-induced senescence as an initial barrier in lymphoma development. Nature 436: 660–665.
Brehm A, Miska EA, McCance DJ, Reid JL, Bannister AJ, Kouzarides T . (1998). Retinoblastoma protein recruits histone deacetylase to repress transcription. Nature 391: 597–601.
Brown JP, Wei W, Sedivy JM . (1997). Bypass of senescence after disruption of p21CIP1/WAF1 gene in normal diploid human fibroblasts. Science 277: 831–834.
Burkhart DL, Sage J . (2008). Cellular mechanisms of tumour suppression by the retinoblastoma gene. Nat Rev Cancer 8: 671–682.
Cales C, Roman-Trufero M, Pavon L, Serrano I, Melgar T, Endoh M et al. (2008). Inactivation of the polycomb group protein Ring1B unveils an antiproliferative role in hematopoietic cell expansion and cooperation with tumorigenesis associated with Ink4a deletion. Mol Cell Biol 28: 1018–1028.
Call JA, Eckhardt SG, Camidge DR . (2008). Targeted manipulation of apoptosis in cancer treatment. Lancet Oncol 9: 1002–1011.
Carragher LA, Snell KR, Giblett SM, Aldridge VS, Patel B, Cook SJ et al. (2010). V600EBraf induces gastrointestinal crypt senescence and promotes tumour progression through enhanced CpG methylation of p16INK4a. EMBO Mol Med 2: 458–471.
Chen H, Gu X, Su IH, Bottino R, Contreras JL, Tarakhovsky A et al. (2009). Polycomb protein Ezh2 regulates pancreatic beta-cell Ink4a/Arf expression and regeneration in diabetes mellitus. Genes Dev 23: 975–985.
Chen Z, Trotman LC, Shaffer D, Lin HK, Dotan ZA, Niki M et al. (2005). Crucial role of p53-dependent cellular senescence in suppression of Pten-deficient tumorigenesis. Nature 436: 725–730.
Chicas A, Wang X, Zhang C, McCurrach M, Zhao Z, Mert O et al. (2010). Dissecting the unique role of the retinoblastoma tumor suppressor during cellular senescence. Cancer Cell 17: 376–387.
Classon M, Harlow E . (2002). The retinoblastoma tumour suppressor in development and cancer. Nat Rev Cancer 2: 910–917.
Classon M, Salama S, Gorka C, Mulloy R, Braun P, Harlow E . (2000). Combinatorial roles for pRB, p107, and p130 in E2F-mediated cell cycle control. Proc Natl Acad Sci USA 97: 10820–10825.
Collado M, Gil J, Efeyan A, Guerra C, Schuhmacher AJ, Barradas M et al. (2005). Tumour biology: senescence in premalignant tumours. Nature 436: 642.
Collado M, Serrano M . (2006). The power and the promise of oncogene-induced senescence markers. Nat Rev Cancer 6: 472–476.
Collado M, Serrano M . (2010). Senescence in tumours: evidence from mice and humans. Nat Rev Cancer 10: 51–57.
Darnell Jr JE. . (2002). Transcription factors as targets for cancer therapy. Nat Rev Cancer 2: 740–749.
del Arroyo AG, El Messaoudi S, Clark PA, James M, Stott F, Bracken A et al. (2007). E2F-dependent induction of p14ARF during cell cycle re-entry in human T cells. Cell Cycle 6: 2697–2705.
Dietrich N, Bracken AP, Trinh E, Schjerling CK, Koseki H, Rappsilber J et al. (2007). Bypass of senescence by the polycomb group protein CBX8 through direct binding to the INK4A-ARF locus. EMBO J 26: 1637–1648.
Engelsen IB, Mannelqvist M, Stefansson IM, Carter SL, Beroukhim R, Oyan AM et al. (2008). Low BMI-1 expression is associated with an activated BMI-1-driven signature, vascular invasion, and hormone receptor loss in endometrial carcinoma. Br J Cancer 98: 1662–1669.
Ernst T, Chase AJ, Score J, Hidalgo-Curtis CE, Bryant C, Jones AV et al. (2010). Inactivating mutations of the histone methyltransferase gene EZH2 in myeloid disorders. Nat Genet 42: 722–726.
Esteller M, Corn PG, Baylin SB, Herman JG . (2001). A gene hypermethylation profile of human cancer. Cancer Res 61: 3225–3229.
Esteller M . (2008). Epigenetics in cancer. N Engl J Med 358: 1148–1159.
Feinberg AP, Ohlsson R, Henikoff S . (2006). The epigenetic progenitor origin of human cancer. Nat Rev Genet 7: 21–33.
Feldser DM, Kostova KK, Winslow MM, Taylor SE, Cashman C, Whittaker CA et al. (2010). Stage-specific sensitivity to p53 restoration during lung cancer progression. Nature 468: 572–575.
Fiskus W, Wang Y, Sreekumar A, Buckley KM, Shi H, Jillella A et al. (2009). Combined epigenetic therapy with the histone methyltransferase EZH2 inhibitor 3-deazaneplanocin A and the histone deacetylase inhibitor panobinostat against human AML cells. Blood 114: 2733–2743.
Fujita K, Mondal AM, Horikawa I, Nguyen GH, Kumamoto K, Sohn JJ et al. (2009). p53 isoforms Delta133p53 and p53beta are endogenous regulators of replicative cellular senescence. Nat Cell Biol 11: 1135–1142.
Gil J, Bernard D, Martinez D, Beach D . (2004). Polycomb CBX7 has a unifying role in cellular lifespan. Nat Cell Biol 6: 67–72.
Gil J, Peters G . (2006). Regulation of the INK4b-ARF-INK4a tumour suppressor locus: all for one or one for all. Nat Rev Mol Cell Biol 7: 667–677.
Gore SD, Baylin S, Sugar E, Carraway H, Miller CB, Carducci M et al. (2006). Combined DNA methyltransferase and histone deacetylase inhibition in the treatment of myeloid neoplasms. Cancer Res 66: 6361–6369.
Guttman M, Amit I, Garber M, French C, Lin MF, Feldser D et al. (2009). Chromatin signature reveals over a thousand highly conserved large non-coding RNAs in mammals. Nature 458: 223–227.
Harley CB, Futcher AB, Greider CW . (1990). Telomeres shorten during ageing of human fibroblasts. Nature 345: 458–460.
Haugstetter AM, Loddenkemper C, Lenze D, Grone J, Standfuss C, Petersen I et al. (2010). Cellular senescence predicts treatment outcome in metastasised colorectal cancer. Br J Cancer 103: 505–509.
Haupt Y, Maya R, Kazaz A, Oren M . (1997). Mdm2 promotes the rapid degradation of p53. Nature 387: 296–299.
Hayden A, Johnson PW, Packham G, Crabb SJ . (2010). S-adenosylhomocysteine hydrolase inhibition by 3-deazaneplanocin A analogues induces anti-cancer effects in breast cancer cell lines and synergy with both histone deacetylase and HER2 inhibition. Breast Cancer Res Treat (e-pub ahead of print; doi:10.1007/s10549-010-0982-0).
Hayflick L, Moorhead PS . (1961). The serial cultivation of human diploid cell strains. Exp Cell Res 25: 585–621.
He L, He X, Lim LP, de Stanchina E, Xuan Z, Liang Y et al. (2007). A microRNA component of the p53 tumour suppressor network. Nature 447: 1130–1134.
Hollstein M, Rice K, Greenblatt MS, Soussi T, Fuchs R, Sorlie T et al. (1994). Database of p53 gene somatic mutations in human tumors and cell lines. Nucleic Acids Res 22: 3551–3555.
Holst CR, Nuovo GJ, Esteller M, Chew K, Baylin SB, Herman JG et al. (2003). Methylation of p16(INK4a) promoters occurs in vivo in histologically normal human mammary epithelia. Cancer Res 63: 1596–1601.
Irelan JT, Gutierrez Del Arroyo A, Gutierrez A, Peters G, Quon KC, Miraglia L et al. (2009). A functional screen for regulators of CKDN2A reveals MEOX2 as a transcriptional activator of INK4a. PLoS One 4: e5067.
Itahana K, Zou Y, Itahana Y, Martinez JL, Beausejour C, Jacobs JJ et al. (2003). Control of the replicative life span of human fibroblasts by p16 and the polycomb protein Bmi-1. Mol Cell Biol 23: 389–401.
Jacobs JJ, Keblusek P, Robanus-Maandag E, Kristel P, Lingbeek M, Nederlof PM et al. (2000). Senescence bypass screen identifies TBX2, which represses Cdkn2a (p19(ARF)) and is amplified in a subset of human breast cancers. Nat Genet 26: 291–299.
Jacobs JJ, Kieboom K, Marino S, DePinho RA, van Lohuizen M . (1999). The oncogene and Polycomb-group gene bmi-1 regulates cell proliferation and senescence through the ink4a locus. Nature 397: 164–168.
Junttila MR, Karnezis AN, Garcia D, Madriles F, Kortlever RM, Rostker F et al. (2010). Selective activation of p53-mediated tumour suppression in high-grade tumours. Nature 468: 567–571.
Karamitopoulou E, Pallante P, Zlobec I, Tornillo L, Carafa V, Schaffner T et al. (2010). Loss of the CBX7 protein expression correlates with a more aggressive phenotype in pancreatic cancer. Eur J Cancer 46: 1438–1444.
Khalil AM, Guttman M, Huarte M, Garber M, Raj A, Rivea Morales D et al. (2009). Many human large intergenic noncoding RNAs associate with chromatin-modifying complexes and affect gene expression. Proc Natl Acad Sci USA 106: 11667–11672.
Kia SK, Gorski MM, Giannakopoulos S, Verrijzer CP . (2008). SWI/SNF mediates polycomb eviction and epigenetic reprogramming of the INK4b-ARF-INK4a locus. Mol Cell Biol 28: 3457–3464.
Kleer CG, Cao Q, Varambally S, Shen R, Ota I, Tomlins SA et al. (2003). EZH2 is a marker of aggressive breast cancer and promotes neoplastic transformation of breast epithelial cells. Proc Natl Acad Sci USA 100: 11606–11611.
Komori H, Enomoto M, Nakamura M, Iwanaga R, Ohtani K . (2005). Distinct E2F-mediated transcriptional program regulates p14ARF gene expression. EMBO J 24: 3724–3736.
Koontz JI, Soreng AL, Nucci M, Kuo FC, Pauwels P, van Den Berghe H et al. (2001). Frequent fusion of the JAZF1 and JJAZ1 genes in endometrial stromal tumors. Proc Natl Acad Sci USA 98: 6348–6353.
Kortlever RM, Higgins PJ, Bernards R . (2006). Plasminogen activator inhibitor-1 is a critical downstream target of p53 in the induction of replicative senescence. Nat Cell Biol 8: 877–884.
Kotake Y, Cao R, Viatour P, Sage J, Zhang Y, Xiong Y . (2007). pRB family proteins are required for H3K27 trimethylation and Polycomb repression complexes binding to and silencing p16INK4alpha tumor suppressor gene. Genes Dev 21: 49–54.
Kotake Y, Zeng Y, Xiong Y . (2009). DDB1-CUL4 and MLL1 mediate oncogene-induced p16INK4a activation. Cancer Res 69: 1809–1814.
Kubbutat MH, Jones SN, Vousden KH . (1997). Regulation of p53 stability by Mdm2. Nature 387: 299–303.
Kuilman T, Michaloglou C, Mooi WJ, Peeper DS . (2010). The essence of senescence. Genes Dev 24: 2463–2479.
Kuilman T, Michaloglou C, Vredeveld LC, Douma S, van Doorn R, Desmet CJ et al. (2008). Oncogene-induced senescence relayed by an interleukin-dependent inflammatory network. Cell 133: 1019–1031.
Kumamoto K, Spillare EA, Fujita K, Horikawa I, Yamashita T, Appella E et al. (2008). Nutlin-3a activates p53 to both down-regulate inhibitor of growth 2 and up-regulate mir-34a, mir-34b, and mir-34c expression, and induce senescence. Cancer Res 68: 3193–3203.
Lachner M, O'Carroll D, Rea S, Mechtler K, Jenuwein T . (2001). Methylation of histone H3 lysine 9 creates a binding site for HP1 proteins. Nature 410: 116–120.
Lazzerini Denchi E, Attwooll C, Pasini D, Helin K . (2005). Deregulated E2F activity induces hyperplasia and senescence-like features in the mouse pituitary gland. Mol Cell Biol 25: 2660–2672.
Lessard J, Sauvageau G . (2003). Bmi-1 determines the proliferative capacity of normal and leukaemic stem cells. Nature 423: 255–260.
Levine AJ . (1997). p53, the cellular gatekeeper for growth and division. Cell 88: 323–331.
Li H, Wang W, Liu X, Paulson KE, Yee AS, Zhang X . (2010). Transcriptional factor 1 targets P16(INK4A), upregulating its expression and consequently is involved in Ras-induced premature senescence. Oncogene 29: 5083–5094.
Liu Y, Sanoff HK, Cho H, Burd CE, Torrice C, Mohlke KL et al. (2009). INK4/ARF transcript expression is associated with chromosome 9p21 variants linked to atherosclerosis. PLoS One 4: e5027.
Loercher AE, Tank EM, Delston RB, Harbour JW . (2005). MITF links differentiation with cell cycle arrest in melanocytes by transcriptional activation of INK4A. J Cell Biol 168: 35–40.
Lowe SW, Sherr CJ . (2003). Tumor suppression by Ink4a-Arf: progress and puzzles. Curr Opin Genet Dev 13: 77–83.
Luo RX, Postigo AA, Dean DC . (1998). Rb interacts with histone deacetylase to repress transcription. Cell 92: 463–473.
Lyden D, Young AZ, Zagzag D, Yan W, Gerald W, O'Reilly R et al. (1999). Id1 and Id3 are required for neurogenesis, angiogenesis and vascularization of tumour xenografts. Nature 401: 670–677.
Maertens GN, El Messaoudi-Aubert S, Racek T, Stock JK, Nicholls J, Rodriguez-Niedenfuhr M et al. (2009). Several distinct polycomb complexes regulate and co-localize on the INK4a tumor suppressor locus. PLoS One 4: e6380.
Maertens GN, El Messaoudi-Aubert S, Elderkin S, Hiom K, Peters G . (2010). Ubiquitin-specific proteases 7 and 11 modulate Polycomb regulation of the INK4a tumour suppressor. EMBO J 29: 2553–2565.
Magnaghi-Jaulin L, Groisman R, Naguibneva I, Robin P, Lorain S, Le Villain JP et al. (1998). Retinoblastoma protein represses transcription by recruiting a histone deacetylase. Nature 391: 601–605.
Majumder PK, Grisanzio C, O'Connell F, Barry M, Brito JM, Xu Q et al. (2008). A prostatic intraepithelial neoplasia-dependent p27 Kip1 checkpoint induces senescence and inhibits cell proliferation and cancer progression. Cancer Cell 14: 146–155.
Martin-Perez D, Sanchez E, Maestre L, Suela J, Vargiu P, Di Lisio L et al. (2010). Deregulated expression of the polycomb-group protein SUZ12 target genes characterizes mantle cell lymphoma. Am J Pathol 177: 930–942.
Matheu A, Klatt P, Serrano M . (2005). Regulation of the INK4a/ARF locus by histone deacetylase inhibitors. J Biol Chem 280: 42433–42441.
Mercer TR, Dinger ME, Mattick JS . (2009). Long non-coding RNAs: insights into functions. Nat Rev Genet 10: 155–159.
Merlo A, Herman JG, Mao L, Lee DJ, Gabrielson E, Burger PC et al. (1995). 5′ CpG island methylation is associated with transcriptional silencing of the tumour suppressor p16/CDKN2/MTS1 in human cancers. Nat Med 1: 686–692.
Messaoudi-Aubert SE, Nicholls J, Maertens GN, Brookes S, Bernstein E, Peters G . (2010). Role for the MOV10 RNA helicase in polycomb-mediated repression of the INK4a tumor suppressor. Nat Struct Mol Biol 17: 862–868.
Michaloglou C, Vredeveld LC, Soengas MS, Denoyelle C, Kuilman T, van der Horst CM et al. (2005). BRAFE600-associated senescence-like cell cycle arrest of human naevi. Nature 436: 720–724.
Moellering RE, Cornejo M, Davis TN, Del Bianco C, Aster JC, Blacklow SC et al. (2009). Direct inhibition of the NOTCH transcription factor complex. Nature 462: 182–188.
Mohammad HP, Cai Y, McGarvey KM, Easwaran H, Van Neste L, Ohm JE et al. (2009). Polycomb CBX7 promotes initiation of heritable repression of genes frequently silenced with cancer-specific DNA hypermethylation. Cancer Res 69: 6322–6330.
Molofsky AV, Pardal R, Iwashita T, Park IK, Clarke MF, Morrison SJ . (2003). Bmi-1 dependence distinguishes neural stem cell self-renewal from progenitor proliferation. Nature 425: 962–967.
Monahan KB, Rozenberg GI, Krishnamurthy J, Johnson SM, Liu W, Bradford MK et al. (2010). Somatic p16(INK4a) loss accelerates melanomagenesis. Oncogene 29: 5809–5817.
Morris EJ, Dyson NJ . (2001). Retinoblastoma protein partners. Adv Cancer Res 82: 1–54.
Mroz EA, Baird AH, Michaud WA, Rocco JW . (2008). COOH-terminal binding protein regulates expression of the p16INK4A tumor suppressor and senescence in primary human cells. Cancer Res 68: 6049–6053.
Muller J, Verrijzer P . (2009). Biochemical mechanisms of gene regulation by polycomb group protein complexes. Curr Opin Genet Dev 19: 150–158.
Narita M, Nunez S, Heard E, Lin AW, Hearn SA, Spector DL et al. (2003). Rb-mediated heterochromatin formation and silencing of E2F target genes during cellular senescence. Cell 113: 703–716.
Narita M, Lowe SW . (2005). Senescence comes of age. Nat Med 11: 920–922.
Narita M, Krizhanovsky V, Nunez S, Chicas A, Hearn SA, Myers MP et al. (2006). A novel role for high-mobility group a proteins in cellular senescence and heterochromatin formation. Cell 126: 503–514.
Negishi M, Saraya A, Mochizuki S, Helin K, Koseki H, Iwama A . (2010). A Novel zinc finger protein Zfp277 mediates transcriptional repression of the Ink4a/Arf locus through polycomb repressive complex 1. PLoS One 5: e12373.
Nielsen SJ, Schneider R, Bauer UM, Bannister AJ, Morrison A, O'Carroll D et al. (2001). Rb targets histone H3 methylation and HP1 to promoters. Nature 412: 561–565.
Ohm JE, McGarvey KM, Yu X, Cheng L, Schuebel KE, Cope L et al. (2007). A stem cell-like chromatin pattern may predispose tumor suppressor genes to DNA hypermethylation and heritable silencing. Nat Genet 39: 237–242.
Ohtani N, Zebedee Z, Huot TJ, Stinson JA, Sugimoto M, Ohashi Y et al. (2001). Opposing effects of Ets and Id proteins on p16INK4a expression during cellular senescence. Nature 409: 1067–1070.
Pallante P, Federico A, Berlingieri MT, Bianco M, Ferraro A, Forzati F et al. (2008). Loss of the CBX7 gene expression correlates with a highly malignant phenotype in thyroid cancer. Cancer Res 68: 6770–6778.
Pantoja C, Serrano M . (1999). Murine fibroblasts lacking p21 undergo senescence and are resistant to transformation by oncogenic Ras. Oncogene 18: 4974–4982.
Park IK, Qian D, Kiel M, Becker MW, Pihalja M, Weissman IL et al. (2003). Bmi-1 is required for maintenance of adult self-renewing haematopoietic stem cells. Nature 423: 302–305.
Pasmant E, Laurendeau I, Heron D, Vidaud M, Vidaud D, Bieche I . (2007). Characterization of a germ-line deletion, including the entire INK4/ARF locus, in a melanoma-neural system tumor family: identification of ANRIL, an antisense noncoding RNA whose expression coclusters with ARF. Cancer Res 67: 3963–3969.
Puppe J, Drost R, Liu X, Joosse SA, Evers B, Cornelissen-Steijger P et al. (2009). BRCA1-deficient mammary tumor cells are dependent on EZH2 expression and sensitive to Polycomb Repressive Complex 2-inhibitor 3-deazaneplanocin A. Breast Cancer Res 11: R63.
Quelle DE, Zindy F, Ashmun RA, Sherr CJ . (1995). Alternative reading frames of the INK4a tumor suppressor gene encode two unrelated proteins capable of inducing cell cycle arrest. Cell 83: 993–1000.
Rea S, Eisenhaber F, O'Carroll D, Strahl BD, Sun ZW, Schmid M et al. (2000). Regulation of chromatin structure by site-specific histone H3 methyltransferases. Nature 406: 593–599.
Reed JC . (2006). Drug insight: cancer therapy strategies based on restoration of endogenous cell death mechanisms. Nat Clin Pract Oncol 3: 388–398.
Riley T, Sontag E, Chen P, Levine A . (2008). Transcriptional control of human p53-regulated genes. Nat Rev Mol Cell Biol 9: 402–412.
Robertson KD, Ait-Si-Ali S, Yokochi T, Wade PA, Jones PL, Wolffe AP . (2000). DNMT1 forms a complex with Rb, E2F1 and HDAC1 and represses transcription from E2F-responsive promoters. Nat Genet 25: 338–342.
Sage J, Miller AL, Perez-Mancera PA, Wysocki JM, Jacks T . (2003). Acute mutation of retinoblastoma gene function is sufficient for cell cycle re-entry. Nature 424: 223–228.
Sauvageau M, Sauvageau G . (2010). Polycomb group proteins: multi-faceted regulators of somatic stem cells and cancer. Cell Stem Cell 7: 299–313.
Schlesinger Y, Straussman R, Keshet I, Farkash S, Hecht M, Zimmerman J et al. (2007). Polycomb-mediated methylation on Lys27 of histone H3 pre-marks genes for de novo methylation in cancer. Nat Genet 39: 232–236.
Schmitt CA . (2007). Cellular senescence and cancer treatment. Biochim Biophys Acta 1775: 5–20.
Schmitt CA, Fridman JS, Yang M, Lee S, Baranov E, Hoffman RM et al. (2002). A senescence program controlled by p53 and p16INK4a contributes to the outcome of cancer therapy. Cell 109: 335–346.
Serrano M, Blasco MA . (2001). Putting the stress on senescence. Curr Opin Cell Biol 13: 748–753.
Serrano M, Lin AW, McCurrach ME, Beach D, Lowe SW . (1997). Oncogenic ras provokes premature cell senescence associated with accumulation of p53 and p16INK4a. Cell 88: 593–602.
Shay JW, Roninson IB . (2004). Hallmarks of senescence in carcinogenesis and cancer therapy. Oncogene 23: 2919–2933.
Sherr CJ . (2006). Divorcing ARF and p53: an unsettled case. Nat Rev Cancer 6: 663–673.
Simon JA, Kingston RE . (2009). Mechanisms of polycomb gene silencing: knowns and unknowns. Nat Rev Mol Cell Biol 10: 697–708.
Sparmann A, van Lohuizen M . (2006). Polycomb silencers control cell fate, development and cancer. Nat Rev Cancer 6: 846–856.
Swarbrick A, Roy E, Allen T, Bishop JM . (2008). Id1 cooperates with oncogenic Ras to induce metastatic mammary carcinoma by subversion of the cellular senescence response. Proc Natl Acad Sci USA 105: 5402–5407.
Tan J, Yang X, Zhuang L, Jiang X, Chen W, Lee PL et al. (2007). Pharmacologic disruption of Polycomb-repressive complex 2-mediated gene repression selectively induces apoptosis in cancer cells. Genes Dev 21: 1050–1063.
Taylor RC, Cullen SP, Martin SJ . (2008). Apoptosis: controlled demolition at the cellular level. Nat Rev Mol Cell Biol 9: 231–241.
te Poele RH, Okorokov AL, Jardine L, Cummings J, Joel SP . (2002). DNA damage is able to induce senescence in tumor cells in vitro and in vivo. Cancer Res 62: 1876–1883.
Timmermann S, Hinds PW, Munger K . (1998). Re-expression of endogenous p16ink4a in oral squamous cell carcinoma lines by 5-aza-2′-deoxycytidine treatment induces a senescence-like state. Oncogene 17: 3445–3453.
Vandel L, Nicolas E, Vaute O, Ferreira R, Ait-Si-Ali S, Trouche D . (2001). Transcriptional repression by the retinoblastoma protein through the recruitment of a histone methyltransferase. Mol Cell Biol 21: 6484–6494.
Vassilev LT, Vu BT, Graves B, Carvajal D, Podlaski F, Filipovic Z et al. (2004). in vivo activation of the p53 pathway by small-molecule antagonists of MDM2. Science 303: 844–848.
Ventura A, Kirsch DG, McLaughlin ME, Tuveson DA, Grimm J, Lintault L et al. (2007). Restoration of p53 function leads to tumour regression in vivo. Nature 445: 661–665.
Vire E, Brenner C, Deplus R, Blanchon L, Fraga M, Didelot C et al. (2006). The Polycomb group protein EZH2 directly controls DNA methylation. Nature 439: 871–874.
Voorhoeve PM, Agami R . (2003). The tumor-suppressive functions of the human INK4A locus. Cancer Cell 4: 311–319.
Vousden KH, Lu X . (2002). Live or let die: the cell's response to p53. Nat Rev Cancer 2: 594–604.
Vousden KH, Prives C . (2009). Blinded by the light: the growing complexity of p53. Cell 137: 413–431.
Wahlestedt C . (2006). Natural antisense and noncoding RNA transcripts as potential drug targets. Drug Discov Today 11: 503–508.
Wei W, Hemmer RM, Sedivy JM . (2001). Role of p14(ARF) in replicative and induced senescence of human fibroblasts. Mol Cell Biol 21: 6748–6757.
Widschwendter M, Fiegl H, Egle D, Mueller-Holzner E, Spizzo G, Marth C et al. (2007). Epigenetic stem cell signature in cancer. Nat Genet 39: 157–158.
Xue W, Zender L, Miething C, Dickins RA, Hernando E, Krizhanovsky V et al. (2007). Senescence and tumour clearance is triggered by p53 restoration in murine liver carcinomas. Nature 445: 656–660.
Yamaguchi J, Sasaki M, Sato Y, Itatsu K, Harada K, Zen Y et al. (2010). Histone deacetylase inhibitor (SAHA) and repression of EZH2 synergistically inhibit proliferation of gallbladder carcinoma. Cancer Sci 101: 355–362.
Yap KL, Li S, Munoz-Cabello AM, Raguz S, Zeng L, Mujtaba S et al. (2010). Molecular interplay of the noncoding RNA ANRIL and methylated histone H3 lysine 27 by polycomb CBX7 in transcriptional silencing of INK4a. Mol Cell 38: 662–674.
Zhang R, Poustovoitov MV, Ye X, Santos HA, Chen W, Daganzo SM et al. (2005). Formation of macroH2A-containing senescence-associated heterochromatin foci and senescence driven by ASF1a and HIRA. Dev Cell 8: 19–30.
Zhang X, Kim J, Ruthazer R, McDevitt MA, Wazer DE, Paulson KE et al. (2006). The HBP1 transcriptional repressor participates in RAS-induced premature senescence. Mol Cell Biol 26: 8252–8266.
Zhao J, Ohsumi TK, Kung JT, Ogawa Y, Grau DJ, Sarma K et al. (2010). Genome-wide identification of polycomb-associated RNAs by RIP-seq. Mol Cell 40: 939–953.
Acknowledgements
We thank Eros Lazzerini and Jean-Christophe Marine for critical reading of the manuscript. Work in the Bracken Lab is supported by Science Foundation Ireland under the Principal Investigator Career Advancement Award (SFI PICA SFI/10/IN.1/B3002), the Health Research Board under the Health Research Awards 2010 (HRA_POR/2010/124), and the Irish Research Council for Science, Engineering and Technology (IRCSET).
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
The authors declare no conflict of interest.
Rights and permissions
About this article
Cite this article
Lanigan, F., Geraghty, J. & Bracken, A. Transcriptional regulation of cellular senescence. Oncogene 30, 2901–2911 (2011). https://doi.org/10.1038/onc.2011.34
Received:
Accepted:
Published:
Issue Date:
DOI: https://doi.org/10.1038/onc.2011.34
Keywords
This article is cited by
-
Senolytic Effect of Cerium Oxide Nanoparticles (CeO2 NPs) by Attenuating p38/NF-кB, and p53/p21 Signaling Pathways
Journal of Cluster Science (2022)
-
PIK3R3 inhibits cell senescence through p53/p21 signaling
Cell Death & Disease (2020)
-
A lowered 26S proteasome activity correlates with mantle lymphoma cell lines resistance to genotoxic stress
BMC Cancer (2017)
-
The homeoprotein SIX1 controls cellular senescence through the regulation of p16INK4A and differentiation-related genes
Oncogene (2016)
-
Myoepithelial and luminal breast cancer cells exhibit different responses to all-trans retinoic acid
Cellular Oncology (2015)
